Evogene (NYSE: EVGN) reported Q2 EPS of ($0.22), $0.11 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $7.71 million versus the consensus estimate of $4.66 million.

For earnings history and earnings-related data on Evogene (EVGN) click here.